Efficacy of a new ready-to-use vaccine against PCV-2d and <i>Mycoplasma hyopneumoniae</i> under experimental conditions. [PDF]
Krejci R +14 more
europepmc +1 more source
Efficacy of a Novel PCV2d and <i>Mycoplasma hyopneumoniae</i> Combined Vaccine in Piglets with High and Low Levels of PCV2 Maternally Derived Antibodies at Vaccination. [PDF]
Sagrera M +9 more
europepmc +1 more source
Exploring the Genetic Diversity of Mycoplasma hyopneumoniae in Pigs with Pneumonia and Pleurisy at Slaughter. [PDF]
Panneitz AK +6 more
europepmc +1 more source
The <i>Mycoplasma hyopneumoniae</i> protein Mhp274 elicits mucosal and systemic immune responses in mice. [PDF]
Xie M +6 more
europepmc +1 more source
A novel intradermal combination vaccine for PCV2 and Mycoplasma hyopneumoniae protection in swine: its use with Lawsonia intracellularis and PRRSV vaccines. [PDF]
Hangalapura BN +3 more
europepmc +1 more source
Related searches:
Antimicrobial treatment of Mycoplasma hyopneumoniae infections
The Veterinary Journal, 2020Mycoplasma hyopneumoniae (M. hyopneumoniae) is the primary agent of enzootic pneumonia, a chronic and economically important respiratory disease of pigs. Control and prevention of M. hyopneumoniae infections can be accomplished by optimization of management and housing conditions, and by vaccination.
Dominiek Maes +3 more
openaire +2 more sources

